Efficacy and Safety of Biosimilar Cetuximab (CETUXA) in Locoregionally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck: A Retrospective Multicenter Analysis..

Authors

  • Dr. Kumar Prabhash, Dr. Rajat Saha, Dr. Priya Priyadarshini Nayak,Dr.Arun Sheshachalam, Dr. Kaushal Babubhai Patel, Dr. Tanveer Maksud, Dr Priyanka Subhagan, Dr. Manthan Mehta, Dr Dattatray Pawar, Dr Akhilesh Sharma Author

DOI:

https://doi.org/10.64149/J.Carcinog.24.10s.382-389

Abstract

Squamous cell carcinoma of the head and neck (SCCHN) cases account for about 5% of all newly diagnosed cancer cases, resulting in more than 300000 deaths per year.1 Despite appropriate primary treatments, in approximately 50% to 60% of patients with stage III to IV disease, locoregional relapse occurs.2

A large proportion of patients presenting with stage I and II squamous cell carcinoma of the head and neck (SCCHN) will remain disease-free after single modality treatment. But the majority of patients present with a more advanced disease stage. Locoregionally advanced, recurrent, and metastatic SCCHN are a challenge to treat.3This subset of patient is not suitable for surgery or radiotherapy. Hence, systemic treatments and best supportive care are the preferred therapeutic options.

Downloads

Published

2025-12-01

Issue

Vol. 24 No. 10s (2025): Journal of Carcinogenesis

Section

Articles

How to Cite

Efficacy and Safety of Biosimilar Cetuximab (CETUXA) in Locoregionally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck: A Retrospective Multicenter Analysis. (2025). Journal of Carcinogenesis, 24(10s), 382-389. https://doi.org/10.64149/J.Carcinog.24.10s.382-389